Eleonora Teplinsky: My top 5 Breast/GYN Cancer Advances in 2023

Eleonora Teplinsky shared on X/Twitter:

“My top 5 Breast/GYN Cancer Advances in 2023–> #4: Updates on Molecular Testing. This year:
– We saw an increased focus on genetic testing to see if a person inherited a genetic mutation that increases cancer risk (still not being done as much as it should).
– Molecular testing of the tumor to guide treatment (i.e., ESR1 mutation for elacestrant in HR+/HER2- metastatic breast cancer, BRCA/HRD testing for potential use of PARP inhibitors in ovarian cancer, MSI/MMR testing in endometrial cancer, and more).
– Increasing use of non-invasive liquid biopsies to guide treatment (and in the future, hopefully screen for recurrence).”

Source: Eleonora Teplinsky/X

Eleonora Teplinsky is a medical oncologist specializing in breast and gynecologic oncology. She is the head of breast and gynecological medical oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, New Jersey, and a clinical assistant professor of medicine at the Icahn School of Medicine at Mount Sinai in New York.

Her clinical and research interests focus on young women with breast cancer, survivorship, exercise oncology, and the use of social media in oncology. She is passionate about oncology education and advocacy on social media and is the host of the INTERLUDE Podcast, where she shares the stories and experiences of those who have been affected by cancer.

Dr. Teplinsky is the co-lead of the The Collaboration for Outcomes using Social Media in Oncology (COSMO) – a social media lab working to provide a venue for social media research in oncology.